Light therapy treatment

• US 8,945,196 B2
• Filed: 04/30/2010
• Issued: 02/03/2015
• Est. Priority Date: 05/01/2009
• Status: Active Grant

• Current Assignee: Wayne State University
• Original Assignee: Wayne State University
• Inventors: Huttemann, Maik, Lee, Icksoo, Kamholz, John, Grossman, Lawrence, Przyklenk, Karin, Sanderson, Thomas
• Primary Examiner(s): VAN ROY, TOD THOMAS
• Application Number:
  US12/771,137
• Publication Number:
  US 20110066213A1
• Time in Patent Office: 1,740 Days
• Field of Search: 606/2, 606/3, 607/88, 607/89
• US Class Current: 607/88
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61N 2005/0626 Monitoring, verifying, controlling systems and methods
• CPC Class Codes: A61N 2005/0643 Applicators, probes irradiating specific body areas in close proximity
• CPC Class Codes: A61N 2005/0652 Arrays of diodes
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 5/0613 Apparatus adapted for a specific treatment

Abstract

An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.

Claims

1. A light therapy device comprising:

a first light source configured to generate light with a first wavelength including 730-770 nm;

a second light source configured to generate light with a second wavelength including 950-970 nm; and

a processor configured to operate the first and second light sources to inhibit cytochrome c oxidase when applied to organic tissue in response to an ischemia-reperfusion event,

wherein the first and second wavelengths are applied at a power density that penetrates tissue of a human patient;

wherein the processor is configured to;

reduce a brightness of the light generated to inhibit cytochrome c oxidase following the inset of reperfusion;

reduce the drightness by individually disabling the light sources at different times; and

reduce the brightness by disabling discrete groups of the light sources at different times.

2. A light therapy device as set forth in claim 1, wherein the light therapy device includes:

a third light source configured to generate light with at least a third wavelength including 850-890 nm; and

a fourth light source configured to generate light with at least a fourth wavelength including 880-920 nm.

3. A light therapy device as set forth in claim 1, wherein the processor is configured to operate the first and second light sources during ischemia, at the onset of reperfusion, after reperfusion, or any combination thereof.

4. A light therapy device as set forth in claim 3, wherein the processor is configured to operate the first and second light sources for at least two consecutive hours following the onset of reperfusion.

5. A light therapy device as set forth in claim 1, wherein the processor is configured to output power densities that are different for each light source.

6. A light therapy device as set forth in claim 1, wherein each light source includes a power density ranging from approximately 200 mW/cm² to approximately 800 mW/cm².

7. A light therapy device as set forth in claim 1, wherein the light therapy device is configured to work with one or more oximeters to monitor oxygen, and the light therapy device further comprises a controller that is configured to prevent light generated during treatment from interfering with light used to measure oxygen saturation.

8. A light therapy device comprising:

light sources configured to generate light in four different wavelengths, each wavelength being selected respectively from ranges 730-770 nm, 850-890 nm, 880-920 nm, and 950-970 nm; and

a processor configured to control operation of at least two of the different wavelengths of the light therapy device to inhibit cytochrome c oxidase when applied to organic tissue during ischemia, at the onset of reperfusion, after reperfusion, or any combination thereof, and apply each of the different wavelengths at a power density that penetrates tissue of a human patient;

wherein the processor is configured to reduce a brightness of the light generated to inhibit cytochrome c oxidase; and

wherein the processor reduces the brightness by individually disabling the light sources at different times.

9. A light therapy device as set forth in claim 8, wherein the light includes a wavelength of approximately 750 nm, approximately 870 nm, approximately 900 nm, and approximately 950 nm.

10. A light therapy device as set forth in claim 8, wherein the light is generated by at least one of a light emitting diode, an optical fiber, and a laser.

11. A light therapy device as set forth in claim 8, wherein the light therapy device includes light sources that are each configured to generate the different wavelengths of light that inhibit cytochrome c oxidase, and wherein the processor controls the light sources such that a power density is different for each light source.

12. A light therapy device as set forth in claim 8, wherein each light source includes a power density ranging from approximately 200 mW/cm² to approximately 800 mW/cm².

13. A light therapy device as set forth in claim 8, wherein the light therapy device is configured to work with one or more oximeters to monitor oxygen, and the light therapy device further comprises a controller that is configured to prevent light generated during treatment from interfering with light used to measure oxygen saturation.

14. A light therapy system comprising:

light sources configured to generated light at wavelengths including 730-779 nm, and 950-970 nm, that inhibits cytochrome c oxidase and at a power density that penetrates the tissue of a patient adjacent to an ischemia-reperfusion event, wherein the light therapy system is configured to monitor oxygen; and

a controller configured to prevent light generated during treatment from interfering with light used to measure oxygen saturation;

further comprising a processor configured to;

reduce a brightness of the light emitted following the onset of reperfusion; and

reduce the brightness by individually disabling the light sources at different times.

15. A light therapy system as set forth in claim 14, further comprising the light sources configured to emit light at different wavelengths, wherein the light sources apply light at power densities that penetrates the bone of a human patient.

16. A light therapy system as set forth in claim 15, wherein each of the light sources includes a power density ranging from approximately 200 mW/cm² to approximately 800 mW/cm².

17. A light therapy system as set forth in claim 15, wherein the processor is further configured to output a power density that is different for each of the light sources.

18. A light therapy system as set forth in claim 14, wherein the light sources include additional light sources that generate light at a wavelength including 850-890 nm, and at a wavelength including 880-920 nm.